SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥141.45-CN¥1.44 (-1.01%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.52% below the high.
Loading market information…
NYSE · CRL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Charles River Laboratories International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Charles River Laboratories International, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $2.97. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Charles River Laboratories International, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $1.03B+6.52% vs estimate |
| Q1 2025 | May 7, 2025 | $2.34+13.59% vs estimate | $984.17M+2.65% vs estimate |
|---|
| Q4 2024 | Feb 19, 2025 | $2.66+6.4% vs estimate | $1.00B+5.73% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | $2.59+7.02% vs estimate | $1.01B+3.46% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
37 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 14 contributors · Median target $326.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥141.45-CN¥1.44 (-1.01%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.52% below the high.
HK$44.24-HK$0.82 (-1.82%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.72% below the high.
$677.56-$15.12 (-2.18%)
Medpace Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.36% below the high.
$215.48+$1.32 (+0.62%)
ICON Public Limited Company’s quoted price sits in the upper half of its reported 52-week range, 1.61% below the high.
HK$66.45-HK$1.45 (-2.14%)
WuXi XDC Cayman Inc’s quoted price sits in the upper half of its reported 52-week range, 22.2% below the high.
HK$35.90-HK$1.80 (-4.77%)
Genscript Biotech Corporation’s quoted price sits in the upper half of its reported 52-week range, 27.42% below the high.
CN¥39.14-CN¥0.86 (-2.15%)
Pharmaron Beijing Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 26.94% below the high.
CN¥48.57+CN¥0.38 (+0.79%)
Hangzhou Tigermed Consulting Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.42% below the high.
